FMP
XETRA
2.11 EUR
-0.01 (-0.474%)
Dr. Selwyn Ho MB BS, MBBS
Healthcare
Biotechnology
https://www.medigene.com
XETRA
Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.
N/A
DE000A1X3W00
N/A
Lochhamer Strasse 11
49 89 2000 330
DE
87
Jun 30, 2000